Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common chronic
liver disease globally and is currently estimated to affect up to 38% of the global adult …

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) pose a
significant threat to human health and cause a tremendous socioeconomic burden …

We aimed to determine the extent of multi-organ fat accumulation and fibro-inflammation in
individuals living with type 2 diabetes. We deeply phenotyped individuals with type 2 …

The collection'New horizons in the diagnosis and management of patients with metabolic
dysfunction-associated steatotic liver disease (MASLD)'that is presented here, deals with the …

Although non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis are
increasingly recognised globally, 1 these terms were updated in June 2023 by an …

For end-stage liver disease in children, living donor liver transplantation (LDLT) is often the
important standard curative treatment. However, there is a lack of research on early recovery …

Background & Aims The aim of this study was to determine whether liver fibrosis is
associated with heart failure in a general population cohort, and if genetic polymorphisms …

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is a
predominant chronic liver condition globally and is strongly associated with obesity …

Abstract Background & Aims This was a randomized, double-blind, placebo-controlled study
to assess the effects of pemvidutide, a glucagon-like peptide-1 (GLP-1)/glucagon dual …

Background: Type 2 diabetes mellitus (T2DM) is often complicated by steatotic liver disease,
cardiovascular disease (CVD), and extrahepatic cancer. We investigated whether FIB-4, an …